BLACK DIAMOND THERAPEUTICS, INC. Revenue
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Revenue of $0 for the 3-month period ending 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2021-03-25
- BLACK DIAMOND THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-12-31 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-09-30 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-06-30 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-03-31 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2018 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 10-K · filed 2021-03-25 |
| 2020-09-30 | $0.00 10-K · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-06-30 | $0.00 10-K · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-03-31 | $0.00 10-K · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 10-K · filed 2021-03-25 |
| 2019-09-30 | $0.00 10-K · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | $0.00 10-K · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | $0.00 10-K · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-24 | $0.00 derived: sum of 2 quarters · filed 2020-03-24 | $0.00 derived: sum of 3 quarters · filed 2020-03-24 | $0.00 10-K · filed 2020-03-24 |
| 2018-09-30 | $0.00 10-K · filed 2020-03-24 | $0.00 derived: sum of 2 quarters · filed 2020-03-24 | $0.00 derived: sum of 3 quarters · filed 2020-03-24 | |
| 2018-06-30 | $0.00 10-K · filed 2020-03-24 | $0.00 derived: sum of 2 quarters · filed 2020-03-24 | ||
| 2018-03-31 | $0.00 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |